In terms of what we know about biology, we’re probably 17 to 20 orders of magnitude away between what we know and what we don't know. We want to see foundation models explode in biology that can understand not just one protein's function, but potentially any protein or any gene, any genome, in any context. We don't have that in biology yet.And so for us to get that right, we need scaled compute, scaled models and the parameters and architectures. And finally scaled data. I think we are living in the most ex ...

[Music] For a long time, I've always thought of as life as a puzzle, but a very special kind of puzzle. A puzzle where we can't see a picture in the box. And why do I say this.So, when we start life, like we're basically just learning new things. We're taking in information from the world. We're seeing the things that we like and the things that we don't like and then we somewhere along the way we come up with our personality or as I would say our way of interacting with the world.So why did I even come up ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 本周 （7 月 7 日-7 月 14 日） ，国际顶尖学术期刊 Cell 共上线了 11 篇研究论文，其中 8 篇来自华人学者，这些研究分别在 结构生物学、AI 蛋 白质进化和设计、AI 基因组模型、脑科学、光遗传学 和 合成生物学 领域取得了新突破。 麻疹病毒聚合酶复合物与非核苷抑制剂的结构及抑制机制 2025 年 7 月 7 日，上海科技大学 张贺桥 / Roger Kornberg 团队在 Cell 期刊发表了题为： Structures of the measles virus polymerase complex with non-nucleoside inhibitors and mechanism of inhibition 的研究论文 【1】 。 该研究解析了 麻疹病毒 （MeV） 聚合酶 复合物及其与非核苷抑制剂结合后的结构，并揭示了抑制机制，为抗病毒药物的理性设计奠定了基础。 AI 蛋白质工程计算模拟方法，实现蛋白质高效进化模拟和功能设计 2025 年 7 月 7 日，中国科学院遗传与发育生物学研究所 高彩霞 团队在国际顶尖学术期刊 Cell 期刊 ...

CARLSBAD, Calif., July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA.Details of the poster presentation are below: Title: "TYR ...

前言 ①数字货币+区块链+华为+数据要素！这家公司在数字货币方面有较深的技术储备；②PCB概念+芯片+光 刻胶+光伏！这家公司与主流PCB制造厂商建立稳定供货关系；③芯片+合成生物+氢能源+储能！公司现 金收购半导体企业股权。 每周日至每周四推送明日股市重大公告！内容包含"停复牌、增减持、投资中标、收购、业绩、解禁、 高送转"等一系列个股利好利空公告，其中重要公告均以红色标注，帮助投资者提前寻找到投资热点， 防范各类黑天鹅事件，并且有充足的时间进行分辨和寻找合适的上市公司。 ...

A New Approach to Interstitial Lung Disease J.P. Morgan Healthcare Conference Sanjay S. Shukla, M.D., M.S., President and CEO January 16, 2025 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "f ...

Precision oncology medicines powered by synthetic lethal insights Corporate Presentation May 2025 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements ...

Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a private placement raising approximately $5.0 million through the sale of shares and warrants, aimed at supporting its cancer drug development efforts [1][3]. Group 1: Private Placement Details - The offering included the sale of 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants [2]. - The Pre-Funded Warrants are immediately exercisable at a price of $0.00001, while the Common Warrants have an initial exercise price of $1.00 per share and expire 60 months after the resale registration statement is effective [2]. - The gross proceeds of approximately $5.0 million consist of $4.0 million paid at closing and $1.0 million to be paid upon the effectiveness of the resale registration statement [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7].

Corporate Presentation June 2025 2 Disclaimer BioAge Labs, Inc. (the "Company") does not (nor their respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation or any other written or oral information made available to any interested party or its advisors and any liability therefor ...

Orcas living in the Salish Sea are making exfoliating brushes out of kelp, a new paper reports. Not bad for an animal with no hands https://t.co/ymgUz7sqUYPhoto: Center for Whale Research/NMFS/NOAA Permit 27038 https://t.co/GSUg41OUVz ...